UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1250703 (State or othe ...

销售业绩 - 公司在2023年第四季度取得了中国市场iPhone销售收入创纪录，达到96.77亿美元[110] 风险因素 - 公司面临的风险包括全球宏观经济因素、供应链问题、COVID-19疫情等[4] 未来展望 - 公司的未来展望受到许多不确定因素的影响，包括研发项目进展、资金筹集、合作关系等[7] 财报电话会议要点 - 公司在财报电话会议中提到了产品候选物和未来产品候选物的临床试验、市场风险、融资需求等[6] - 公司在财报电话会议中提到了未来市场风险、员工招聘、财务表现和资金需求等方面的关键要点[6] - 公司在财报电话会议中提到了全球宏观经济因素、临床试验进展、合作关系、资金筹集等关键要点[6] 公司财务状况 - 截至2023年3月31日，ESSA PHARMA INC.的现金及现金等价物为4430.68万美元，较2022年9月30日的5707.65万美元有所下降[19] - ESSA PHARMA INC.在2023年第一季度和前六个月的研发支出分别为448.08万美元和982.51万美元，较去年同期有所减少[20] - ESSA PHARMA INC.在2023年前六个月的经营活动中，现金净流出为1196.89万美元，主要由于购买短期投资导致[21] 股票期权和股权支付 - 公司股票期权交易总数为804.5274万，行权价格为5.08美元，可行权数量为530.2472万[47] - 公司股票期权授予数量为19.5万，每份期权的加权平均公允价值为2.76美元[48] - 公司股票期权授予和行权的股权支付费用分别为1.4362万和1.8541万美元[49] 财务工具和风险管理 - 公司的财务工具主要包括现金及现金等价物、短期投资、应收账款和应付账款及应计负债[52] - 公司的信用风险主要集中在现金、短期投资和应收账款等金融工具上[54] - 公司的流动性风险管理方法是确保在到期时有足够的流动性来支付负债，截至2023年3月31日，公司的营运资本为155,967,246美元[56] - 公司的市场风险主要来自市场因素的变化，如利率和外汇汇率[57] - 公司的外汇风险暴露主要涉及以加拿大元和欧元计价的净货币资产，公司将其现金及现金等价物以美元持有，并根据需要转换以支付加元支出，加元兑美元汇率的10%变动将导致净收益波动1,988美元[59]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1250703 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares EPIX Nasdaq Capital Market ESSA ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1250 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-125 ...

NASDAQ: EPIX O P P E NHE IMER'S 3 2 n d A N N UAL H E A LT H CA RE C O N FERENC E M A RC H 1 5- 17, 2 0 22 Forward Looking Statements 2 Certain written statements in and/or oral statements made in connection with this presentation may be considered forward-looking statements within the meaning of applicable Canadian securities laws and the United States securities laws, that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-2569713 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-2569 ...